Unpacking the Pulse: Janus Henderson's Life Sciences Playbook for Q3 2025

The Dividend Whisper: Unpacking November's Expected Payout Hikes and What They Mean for Your Portfolio

The Unyielding Pillars: Why Dividend Aristocrats Endure (And Thrive Towards 2025)

The Steady Drumbeat of Dividends: Unearthing This Week's Income Royalty

The Unstoppable Ascent: How Linzess Propelled Ironwood to Staggering Heights

AbbVie's High-Stakes Forecast: A Boost That Still Left the Market Wanting More

Tariff Relief: US Postpones Duties on Singaporean Pharma Amidst Supply Chain Concerns

Unlock Financial Freedom: Crafting Your $500,000 Low-Stress Retirement Portfolio for Lasting Peace of Mind

A Pivotal Moment: HHS Advances Major Drug Pricing Rule for Review

Pharma's Big Win: How a Judge's Ruling Ignited Big Pharma Stocks

Thinking of Ditching SCHD? Why QDVO Might Be Your Unexpected Income Powerhouse!

Trump's Bold Vision: Pushing for Direct Drug Deals to Slash Costs

Historic Shift: White House Reviews Landmark Drug Price Negotiation Rule

The Drumbeat of Disinflation: Why the Federal Reserve is Poised to Cut Rates Once More

Healthcare Shorts Take a Breather, But Moderna Remains Under the Microscope

Navigating the Path to Approval: Why REGENXBIO (RGNX) Remains a Strong Investment with RGX-121 for Hunter Syndrome